Session 6A: Challenges in bringing new diagnostic products to market
Tracks
Track 1
| Thursday, May 21, 2026 |
| 1:40 PM - 2:25 PM |
Overview
Sponsored by: SEERPHARMA
Details
The potential of advanced diagnostic tests to address unmet patient needs is growing rapidly as new and existing technologies are applied as we gain a greater understanding of disease processes.
Simply put you only need to do three things well to successfully commercialise a new DX.
Prove that your test will impact on decisions that clinicians make and the way the patient is cared for.
Demonstrate that the test result will do no harm and have an impact on the economics of the disease and not only saving lives but money. This is key to regulatory clearance, demonstrating the value of the test, justifying its price and acquire reimbursement
Develop distribution and Key Opinion Leader strategies to promote adoption of the Dx.
Our panel of industry veterans will dissect these statements and highlight where the simple is in fact hard and the easy has not so much especially the landmines!
Session sponsor:
Speaker
Peter Bradley
Principal
Qatalyst Consulting
Chair
Dr. Anya Jones
Founder and CEO
Respiradigm Pty Ltd
Panellist
Dr. Kieran Mulroney
Founder and CEO
Cytophenix Pty Ltd
Panellist